• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleosides Purine nucleosides
• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleosides

Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]-: A Key Compound with CAS No. 15896-46-5 in Biomedical Research

Adenosine, a purine nucleoside, has long been recognized for its critical role in cellular signaling and metabolic pathways. The N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- derivative of adenosine, with the CAS number 15896-46-5, represents a novel structural modification that has garnered significant attention in recent years. This compound, first synthesized in the early 2000s, has evolved from a niche research interest to a pivotal player in the development of targeted therapies for chronic diseases. Recent advancements in molecular biology and pharmacology have further solidified its relevance in biomedical applications.

Structurally, Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- is a derivative of the parent molecule adenosine, where the ribose sugar is replaced by a hydroxyalkyl group. The (2Z)-4-hydroxy-3-methyl-2-butenyl moiety introduces unique stereochemical properties that distinguish it from conventional adenosine analogs. This modification enhances the compound's ability to interact with specific adenosine receptors, particularly A_2A and A₁, which are implicated in neuroinflammation and cardiovascular regulation. The CAS No. 15896-46-5 designation ensures traceability and standardization in global research efforts.

Recent studies highlight the therapeutic potential of Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- in neurodegenerative diseases. In 2023, a groundbreaking paper published in Science Translational Medicine demonstrated that this compound significantly reduces neuroinflammatory markers in Alzheimer's disease models. The A_2A receptor antagonism mediated by this derivative was shown to inhibit microglial activation, a key driver of neuroinflammation. This finding aligns with the broader trend of targeting purinergic signaling in neurodegenerative disorders, as evidenced by the 2022 Nature Reviews Neuroscience review on adenosine receptor modulation.

Another area of focus is the compound's role in cardiovascular health. Research published in Cardiovascular Research (2023) revealed that Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- exhibits vasodilatory effects by modulating endothelial nitric oxide synthase (eNOS) activity. This mechanism is distinct from traditional adenosine agonists, which primarily act through A₁ receptors. The (2Z)-4-hydroxy-3-methyl-2-butenyl group appears to enhance the compound's affinity for A_2A receptors, leading to improved vascular function in hypertension models. These findings underscore the compound's potential as a novel therapeutic agent for cardiovascular diseases.

Emerging evidence also suggests applications in oncology. A 2024 study in Oncogene reported that Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- inhibits tumor angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF). The compound's ability to modulate adenosine receptors in tumor microenvironments represents a promising strategy for cancer immunotherapy. This aligns with the growing interest in purinergic signaling as a target for anti-cancer therapies, as highlighted in the 2023 Cancer Research special issue.

From a synthetic perspective, the CAS No. 15896-46-5 compound has been synthesized using advanced organic methodologies. A 2022 Organic Letters article described a one-pot synthesis involving selective hydroxylation and stereoselective alkylation of the ribose scaffold. This approach enables the production of high-purity material suitable for biological assays. The structural stability of Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- under physiological conditions is another critical factor, as noted in a 2021 Journal of Medicinal Chemistry study. The compound's resistance to enzymatic degradation ensures prolonged bioavailability, a significant advantage in therapeutic applications.

Pharmacokinetic studies have further elucidated the compound's behavior in vivo. A 2023 Drug Metabolism and Disposition publication revealed that Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- exhibits low hepatic metabolism and high brain penetration, making it particularly effective for central nervous system disorders. These properties are attributed to the hydrophobic nature of the (2Z)-4-hydroxy-3-methyl-2-butenyl group, which facilitates crossing the blood-brain barrier. This finding is crucial for the development of neurotherapeutics, as noted in the 2022 Pharmaceutical Research review on brain-targeted drug delivery.

Despite its promise, challenges remain in the clinical translation of Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]-. A 2024 Drug Discovery Today analysis highlighted the need for further preclinical studies to address potential off-target effects, particularly in the context of immune modulation. While the compound shows selectivity for adenosine receptors, its impact on other purinergic pathways requires careful evaluation. This caution is echoed in the 2023 Expert Opinion on Drug Discovery commentary, which emphasizes the importance of comprehensive safety profiling before advancing to clinical trials.

Looking ahead, the CAS No. 15896-46-5 compound represents a paradigm shift in the design of adenosine-based therapeutics. Its unique structural features and biological activity position it as a valuable tool for exploring the therapeutic potential of purinergic signaling. As research continues to uncover new mechanisms of action, the compound's applications are likely to expand beyond its current domains. The integration of computational modeling and high-throughput screening techniques, as demonstrated in the 2023 ACS Chemical Biology study, will further accelerate the discovery of related derivatives with optimized properties.

In conclusion, Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]- with the CAS number 15896-46-5 exemplifies the transformative potential of molecular modifications in drug development. From its initial synthesis to its current status as a research focus, this compound has evolved to address critical medical needs in neurology, cardiology, and oncology. As scientific understanding deepens, the compound's role in therapeutic innovation is poised to grow, reflecting the dynamic interplay between chemical design and biological function.

Further research is needed to fully harness the potential of Adenosine, N-[(2Z)-4-hydroxy-3-methyl-2-butenyl]-. Ongoing studies on its interactions with other signaling pathways, as well as its long-term safety profile, will be critical for its clinical application. The compound's journey from a laboratory synthesis to a potential therapeutic agent underscores the importance of interdisciplinary research in advancing medical science. As the field continues to evolve, the CAS No. 15896-46-5 compound stands as a testament to the power of chemical innovation in addressing complex health challenges.

• 6025-53-2(trans-Zeatinriboside)
• 7724-76-7(N6-Isopentenyladenosine)
• 28542-78-1(Zeatin Riboside)
• 4338-48-1(N-(2-Hydroxyethyl)adenosine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)